Case Studies
Real-world commercial challenges where market behavior required looking beyond clinical evidence alone.
Independent Portfolio Assessment — Anavex Life Sciences
Independent assessment of Anavex’s four clinical programs—integrating development risk, investment, competition and commercial opportunity into an actionable portfolio strategy.
Read Case StudyWhen Product Demand Is Not Enough
Restored formulary access at a military institution by reframing a demand problem as an institutional commercialization challenge—and engaging the stakeholders who could reverse the decision.
Read Case StudyLeading a Nationally Successful Launch During COVID-19
Led a newly hired team through a remote XCOPRI launch during COVID-19—building account management, solving patient-access barriers and achieving #1 national launch performance.
Read Case StudyTurning a Market Access Barrier into Commercial Growth
Identified an FEP reimbursement barrier in Washington, DC, collaborated with Market Access to improve formulary access and helped approximately double territory sales—with All-Star recognition for three consecutive years.
Read Case StudyRemoving an Institutional Purchasing Barrier
Identified an institutional VA purchasing barrier, escalated through the VISN structure and helped contribute to approximately 250% regional sales growth.
Read Case StudyWhen Clinical Results Don't Drive Adoption
When strong clinical evidence does not produce expected adoption, look beyond the trial—examine non-adopters, treatment pathways and the broader competitive environment.
Read Case Study